当地时间2月6日,“英国制药巨头”阿斯利康在披露2024年第四季度及全年财报时,对涉嫌非法进口药品事宜进行回应。阿斯利康于2025年1月收到深圳海关出具的《移送审查起诉告知书》及《鉴定意见通知书》,公司涉嫌偷逃进口税款,金额为90万美元(约合人民币656万元)。财报显示,偷逃税款主要涉及的两款药物为Imfinzi(度伐利尤单抗)和Imjudo(替西木单抗)。其中,Imfinzi在2024年为公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.